Corporate Symposia
Corporate Symposia provides attendees with additional education and information opportunities.
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate and cannot be accommodated.
All events held at the JW Marriott Hotel. Doors will open 45 minutes before scheduled start time and will include a buffet dinner.
SEATING IS FIRST COME, FIRST SERVE • 1.5 CE AVAILABLE PER SESSION.
Saturday, August 5
- CS01
- Standardized Glucose Reporting – The New EKG for Diabetes
JW Grand Ballroom 1-5, Level 3
Supported by an unrestricted education grant provided by Abbott and Dexcom
This activity is joint-provided by the American Association of Diabetes Educators
and Americal Association of Clinical Endocrinologists
LEARNING OBJECTIVES
- Describe the concept of going “beyond A1c.”
- Identify the plethora of available glucometric techniques.
- Recognize the value of a standard graphical glucometric presentation.
This corporate symposium will address the importance of offering a standard format for blood glucose reporting, no matter the device.Because various glucose meters, CGMs and now Flash Glucose Monitoring (FGM) report in different formats, it is difficult for the providers and patients to navigate the reports.In turn, that has made it difficult to use the technology to promote quality, safety and improve health outcomes.Through lectures and case studies, attendees will learn how standardized reporting like Ambulatory Glucose Profile (AGP) may drive efficiency and provide better therapeutic advantages to patients with diabetes and their healthcare providers.
Presenters
Timothy S. Bailey, MD, FACP, FACE, ECNU Director, AMCR Institute Clinical Associate Professor of Medicine, University of California
Richard M. Bergenstal, MD, Executive Director, International Diabetes Center
George Grunberger, MD, FACP, FACE, Chairman, Grunberger Diabetes Institute
Amy Hess Fischl, MS, RDN, LDN, BC-ADM, CDE, Teen Transition Program Coordinator, University of Chicago Kovler Diabetes
UPN: 0069-9999-17-230-L01-P LNC: 5190
Sunday, August 6
- CS02
- Improving Adherence with New Fixed-Dose Insulin Combination Therapy
JW Grand Ballroom 1-5, Level 3
Supported by an unrestricted education grant provided by Sanofi
This activity is joint-provided by the American Association of Diabetes Educators and Medscape Education.
LEARNING OBJECTIVES
- Describe the safety and efficacy data for new injectable fixed-dose insulin combination therapeutic regimens.
- Describe barriers related to effective insulin use in T2D management.
- Interpret when and how to manage T2D with new fixed-dose insulin combination regimens.
In this Corporate Symposium, the learner will demonstrate greater competence in overcoming barriers related to effective insulin use in T2D management.New insulin + GLP-1 receptor agonist combination therapies have the potential to revolutionize diabetes management.When available, clinicians —especially diabetes educators — will be required to have a deep understanding of the clinical safety and efficacy these new products so they can educate patients appropriately.
Presenters
Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Medical Group
Curtis Triplitt, PharmD, CDE, Clinical Associate Professor, UTHSCSA/Texas Diabetes Institute
Margaret Powers, PhD, RD, CDE, Clinician/Research Scientist, Powers and Associates
UPN: 0069-9999-17-220-L01-P LNC: 5190
- CS03
- Zeroing in on AIC Targets: Pinpointing the Optimal Basal Insulin Strategy in Every Patient with Type 2 Diabetes
JW Grand Ballroom 6-10, Level 3
Suppported by an unrestricted education grant provided by Sanofi
This activity is joint-provided by the American Association of Diabetes Educators and E+S MedEd Group, Inc.
For session information, please see the mobile app.
Learning Objectives
- Review the pathophysiology of T2DM and the effects of insulin therapy on the underlying mechanisms of this disease
- Describe the underlying causes of clinical inertia and psychological insulin resistance as it relates to initiation and/or intensification of insulin and strategies to mitigate these effectors
- Compare and contrast current guideline recommendations for the initiation and intensification of insulin therapy with a focus on basal insulins
Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality in the United States, but these effects are largely preventable with good glycemic control via insulin and other antihyperglycemic agents. Still, only about half of Americans with diabetes achieve target glycemic goals. This phenomenon is partially attributed to delayed insulin initiation and intensification, as well as suboptimal insulin use. Basal insulins have been designed to provide ongoing flat, long-acting insulin levels paralleling natural insulin release, but challenges associated with the utilization of these drugs continue to negatively affect their use. This program is designed to help educate healthcare professionals about strategies associated with optimal basal insulin utilization in patients with T2DM. An audience response system will be utilized presenting questions to the learners for their responses, followed by faculty discussion, reinforcing ideal methods of patient and disease management from each of their perspectives.
UPN#: 0069-9999-17 -250-L01-P LNC:# 5190
